FFAR1; FFAR4; DRD4; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; GPBAR1; HCAR2; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
ALPI; RECQL; TDP1; PLA2G1B; PLA2G2A; CTDSP1; P4HB; PKM; ADK; PIK3R1; GLO1; HPGD; MPO; HSD17B1; CBR1; AKR1B1; HSD17B10; ALOX15; AKR1B10; HSD11B1; ALDH1A1; HSD17B2; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; APEX1; CD38; POLB; | |
PTPRF; PTPN1; PTPN2; ACP1; | |
ACHE; GAA; | |
CFTR; | |
TRPA1; | |
NEK6; AKT1; MET; CSNK2A1; DAPK1; SYK; AXL; FLT3; CAMK2B; SRC; IGF1R; PTK2; AURKB; GSK3B; KDR; CDK1; MAPK1; PIM1; NUAK1; ALK; NEK2; CDK6; PKN1; | |
CA5B; CA3; CA14; CA7; CA5A; CA9; CA4; CA6; CA2; CA12; CA1; | |
AR; NR3C2; PGR; NR3C1; | |
NR1I2; | |
ESRRA; | |
PPARA; PPARG; PPARD; | |
RORC; | |
ESR1; ESR2; | |
NR1H4; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; PTGS2; TYR; XDH; | |
CASP7; CASP1; | |
MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
SLC28A2; SLC28A1; SLC28A3; SLC22A3; SLC22A1; SLCO1B3; SLCO1B1; | |
ABCC1; ABCG2; | |
LMNA; SERPINA6; FABP4; MAPT; FABP3; FABP5; THPO; SIGMAR1; HTT; NPC1; FABP2; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | PLA2G2A | Phospholipase A2 group IIA | P14555 | CHEMBL3474 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
SLC superfamily of solute carriers | SLC22A1 | Solute carrier family 22 member 1 | O15245 | CHEMBL5685 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.331E-13 | 1.225E-10 | ADORA2A, AURKB, CA2, CA7, CFTR, HCAR2, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.640E-12 | 4.303E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.611E-12 | 6.462E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.745E-12 | 6.715E-10 | ABCG2, ACHE, ADORA2A, ADRA2A, ADRA2C, AKT1, ALK, APP, CAMK2B, CASP1, CD38, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, HPGD, HTT, IGF1R, KDR, L3MBTL1, MAPK1, MAPT, MET, MMP9, NFKB1, PARP1, PGR, PKM, PPARG, PTGS2, PYGL, SLC22A1, SMN1, SMN2, STAT6, TP53, TRPA1, TTR, TYR, USP2, XDH |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.524E-11 | 9.695E-09 | AR, CDK1, ESR1, ESR2, ESRRA, NR1H4, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, RORC |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.566E-11 | 9.695E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.980E-11 | 1.448E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
MF | Unclassified; | GO:0004872; receptor activity | 1.686E-10 | 2.603E-08 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, ESRRA, FFAR1, FFAR4, FLT3, GPBAR1, HCAR2, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, NR1H4, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, PTPRF, RORC, SIGMAR1, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.264E-10 | 3.400E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.945E-10 | 9.695E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.310E-09 | 4.966E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.450E-08 | 2.459E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.596E-08 | 3.528E-06 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.383E-08 | 6.017E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.065E-07 | 9.467E-06 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, APP, AXL, BACE1, CFTR, DRD4, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPC1, NPSR1, PTPRF, SIGMAR1, SLC22A1, SLC22A3, SLC28A1, SLC28A2, SLC28A3, SLCO1B1, SLCO1B3, TLR2, TRPA1, TSHR |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.153E-07 | 1.016E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.396E-07 | 1.187E-05 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.964E-07 | 1.633E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.021E-07 | 1.661E-05 | ADK, AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, CAMK2B, CASP7, CDK1, CDK6, CSNK2A1, CTDSP1, ESR1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, HPGD, HTT, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1H4, NR1I2, NR3C1, NR3C2, NUAK1, PARP1, PGR, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.070E-07 | 1.694E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT, NR3C1 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.421E-07 | 1.961E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.865E-07 | 3.038E-05 | ABCC1, ADORA1, ADRA2A, CA2, CA4, CA9, HPGD, SLC22A1, SLCO1B1, SLCO1B3, TSHR |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 7.566E-07 | 5.455E-05 | ADRA2A, AKT1, FFAR1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
MF | GO:0005488; binding | GO:0005524; ATP binding | 9.707E-07 | 6.796E-05 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TP53 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.002E-06 | 6.971E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1, SYK |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.171E-06 | 7.992E-05 | ADORA1, ADORA2A, CA2, CA7, HTT, KDR, NPSR1, PARP1, PLA2G1B, SRC, TRPA1 |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.416E-06 | 9.369E-05 | ADORA1, ADORA2A, DRD4, PPARA, PPARG, RORC, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.027E-06 | 1.276E-04 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.171E-06 | 1.347E-04 | ACHE, ADORA1, ADRA2A, APEX1, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, P4HB, PIK3R1, PKM, PPARA, PTPN1, PTPN2, PTPRF, SRC, SYK, TLR2, TSHR |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.222E-06 | 1.371E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.223E-06 | 1.371E-04 | AKT1, HIF1A, LMNA, P4HB, PPARD, PTGS2, SRC, TP53 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.567E-06 | 1.557E-04 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 3.323E-06 | 1.961E-04 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AHR, AXL, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, PPARG, TLR2, TP53, TTR, TYR |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.393E-06 | 1.997E-04 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 4.490E-06 | 2.553E-04 | AKR1B1, AKT1, AR, CFTR, NR3C1, PPARG, SRC |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.306E-06 | 2.903E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 6.705E-06 | 3.578E-04 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 7.895E-06 | 4.173E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 8.021E-06 | 4.229E-04 | ACP1, ADK, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CBR1, CDK1, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, NR3C1, NR3C2, PGR, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN2, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.440E-06 | 4.890E-04 | CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.043E-05 | 5.344E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.055E-05 | 5.383E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.103E-05 | 5.596E-04 | ADRA2C, AKT1, ALOX12, APP, AR, AXL, CA2, CAMK2B, CDK1, CDK6, CTDSP1, CYP1B1, ESR1, ESRRA, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, NR1H4, PIK3R1, PIM1, PPARD, PPARG, PTGS2, PTK2, PTPN2, PTPRF, SRC, STAT6, SYK, THPO, TLR2, XDH |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.510E-05 | 7.374E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.591E-05 | 7.714E-04 | APP, CDK1, MAPK1, PARP1, PIK3R1, PTGS2, TLR2 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.835E-05 | 8.629E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.894E-05 | 8.849E-04 | ADORA1, ADORA2A, ADORA3, APP, AR, CDK6, CYP1B1, FABP3, LMNA, NOX4, PKN1, PPARD, PPARG, PTGS2, PTPN2, TLR2, TP53, XDH |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.054E-05 | 9.455E-04 | CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HSD11B1, HSD17B2, NOX4, NR3C2, PLA2G2A, PTGS1, PTGS2, SIGMAR1, SLC28A3 |
BP | GO:0032502; developmental process | GO:0007568; aging | 2.102E-05 | 9.638E-04 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.146E-05 | 9.816E-04 | ABCG2, APP, CA12, CA2, CA7, CD38, CFTR, DRD4, ESR1, HIF1A, HTT, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPA1 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.314E-05 | 1.050E-03 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.344E-05 | 1.059E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1, SYK |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.465E-05 | 1.109E-03 | ADORA1, ADRA2A, CD38, PARP1, SRC, TNKS, TNKS2, TRPA1 |
BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 2.715E-05 | 1.206E-03 | ADORA1, ADORA2A, ADRA2A, AKT1, CFTR, DRD4, FFAR1, HTT, NPSR1, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0050995; negative regulation of lipid catabolic process | 2.810E-05 | 1.244E-03 | ADORA1, ADRA2A, AKT1, HCAR2 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.918E-05 | 1.286E-03 | ADRA2A, ADRA2C, DRD4 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.082E-05 | 1.348E-03 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, GPBAR1, HCAR2, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, PPARG, PTPRF, SIGMAR1, TSHR |
BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 3.156E-05 | 1.375E-03 | AHR, AKT1, APP, AR, ESR1, ESRRA, HIF1A, MET, MMP12, NFKB1, NR1H4, NR1I2, NR3C1, PARP1, PGR, PIK3R1, PLA2G1B, PPARA, PPARG, STAT6, TLR2, TNKS, TP53 |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 3.380E-05 | 1.455E-03 | DRD4, NMUR2, PLA2G1B, PLA2G2A |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.712E-05 | 1.591E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM, PPARG |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.995E-05 | 1.702E-03 | IGF1R, KDR, PTK2, SRC, SYK |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 4.351E-05 | 1.822E-03 | ADORA2A, APP, MAPT |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 4.351E-05 | 1.822E-03 | ADORA1, ADORA2A, ADORA3 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 4.351E-05 | 1.822E-03 | NR1H4, PLA2G1B, PYGL |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 4.626E-05 | 1.926E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.768E-05 | 1.975E-03 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 4.901E-05 | 2.021E-03 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 5.920E-05 | 2.361E-03 | AXL, FLT3, FUT7, GLO1, MMP9, PARP1, PIK3R1, PPARG, PTPN2, RORC |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 6.178E-05 | 2.428E-03 | CA2, CA7, CFTR |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 6.178E-05 | 2.428E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 6.178E-05 | 2.428E-03 | ABCC1, ABCG2, NR1I2 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 6.531E-05 | 2.518E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 6.531E-05 | 2.518E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 6.649E-05 | 2.518E-03 | SLC28A2, SLC28A3 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.649E-05 | 2.518E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 6.649E-05 | 2.518E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0033764; steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 6.531E-05 | 2.518E-03 | HSD11B1, HSD17B1, HSD17B10, HSD17B2 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.649E-05 | 2.518E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.649E-05 | 2.518E-03 | ESR1, ESR2 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 6.649E-05 | 2.518E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 6.649E-05 | 2.518E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 6.649E-05 | 2.518E-03 | SLC28A2, SLC28A3 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 7.078E-05 | 2.671E-03 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB, TYR |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 7.571E-05 | 2.833E-03 | AKT1, FABP3, PPARA, PPARG |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 7.571E-05 | 2.833E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 7.913E-05 | 2.943E-03 | AKT1, APP, AXL, CA2, CD38, HCAR2, HIF1A, MAPK1, MMP12, MMP2, NFKB1, NR1H4, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, SYK, THPO, TLR2, TP53 |
BP | GO:0008152; metabolic process | GO:0000122; negative regulation of transcription from RNA polymerase II promoter | 7.921E-05 | 2.943E-03 | AR, AURKB, ESR1, ESR2, ESRRA, MMP12, NFKB1, NR1H4, NR3C1, PARP1, PPARA, PPARD, PPARG, PTPN2, RORC, STAT6, TP53, USP2 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 8.444E-05 | 3.101E-03 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 8.444E-05 | 3.101E-03 | CBR1, PTGS1, PTGS2 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 8.444E-05 | 3.101E-03 | GSK3B, HTT, MAPT |
BP | GO:0009987; cellular process | GO:0010743; regulation of macrophage derived foam cell differentiation | 8.727E-05 | 3.146E-03 | NFKB1, PLA2G2A, PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 9.624E-05 | 3.413E-03 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0009987; cellular process | GO:1901214; regulation of neuron death | 9.993E-05 | 3.508E-03 | ADORA2A, AKT1, AXL, GSK3B, HIF1A, MAPT, PARP1, PPARA, SIGMAR1, TP53 |
BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 1.038E-04 | 3.619E-03 | AKR1B1, AKT1, CYP19A1, CYP1A2, GAA, GSK3B, NOX4, PKM, PPARD, PYGL, XDH |
BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 1.040E-04 | 3.619E-03 | ADORA2A, ADRA2A, CAMK2B, DRD4, FFAR1, HTT, NPSR1, PLA2G1B, PTGS2 |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 1.119E-04 | 3.874E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.142E-04 | 3.927E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.149E-04 | 3.939E-03 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1, PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.191E-04 | 4.077E-03 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.205E-04 | 4.119E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.299E-04 | 4.359E-03 | AKT1, HIF1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 1.319E-04 | 4.413E-03 | ADORA1, ADORA2A, ALOX15, AXL, CDK6, CYP19A1, MMP12, PIK3R1, PKN1, PPARG, PTPN2, STAT6 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.446E-04 | 4.778E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.446E-04 | 4.778E-03 | ADORA2A, CA2, CA7 |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 1.446E-04 | 4.778E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0006775; fat-soluble vitamin metabolic process | 1.466E-04 | 4.800E-03 | CBR1, CYP1A1, CYP3A4, PPARD |
BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.466E-04 | 4.800E-03 | HIF1A, PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.466E-04 | 4.800E-03 | AKT1, PPARA, PTPN2, SRC |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.466E-04 | 4.800E-03 | ADRA2C, AKT1, CD38, PTGS2 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.651E-04 | 5.381E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.829E-04 | 5.884E-03 | CYP19A1, ESR1, SRC |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 1.847E-04 | 5.913E-03 | ABCC1, ABCG2, FABP3, HTT, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.984E-04 | 6.145E-03 | APP, TLR2 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.984E-04 | 6.145E-03 | SLC28A1, SLC28A3 |
BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 1.984E-04 | 6.145E-03 | AR, PGR |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.984E-04 | 6.145E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.984E-04 | 6.145E-03 | SLC28A1, SLC28A3 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.984E-04 | 6.145E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.984E-04 | 6.145E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.984E-04 | 6.145E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.984E-04 | 6.145E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.984E-04 | 6.145E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.984E-04 | 6.145E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.984E-04 | 6.145E-03 | GPBAR1, NR1H4 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.984E-04 | 6.145E-03 | ADORA1, ADORA2A |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 2.026E-04 | 6.257E-03 | CDK6, GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.026E-04 | 6.257E-03 | AKT1, AR, DAPK1, HTT, LMNA, SRC |
BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 2.069E-04 | 6.349E-03 | AKT1, CASP1, MPO, NFKB1, PPARG, PTGS2, SRC, TRPA1 |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 2.070E-04 | 6.349E-03 | CA2, CD38, SRC, SYK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.217E-04 | 6.752E-03 | ALOX15, APP, FFAR4, KDR, NOX4, PLA2G2A, SRC, THPO |
BP | GO:0050896; response to stimulus | GO:0009266; response to temperature stimulus | 2.373E-04 | 7.188E-03 | ADORA1, AKT1, MAPT, PPARG, PTGS2, TP53, TRPA1 |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.493E-04 | 7.497E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG, SYK |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 2.561E-04 | 7.683E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 2.561E-04 | 7.683E-03 | MMP2, MMP9, PPARD, PTGS2 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.574E-04 | 7.698E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 2.679E-04 | 7.991E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, PKM, PPARD |
MF | GO:0005488; binding | GO:0002039; p53 binding | 2.710E-04 | 8.073E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0030540; female genitalia development | 2.781E-04 | 8.238E-03 | AXL, CYP19A1, ESR1 |
BP | GO:0032501; multicellular organismal process | GO:0045986; negative regulation of smooth muscle contraction | 2.781E-04 | 8.238E-03 | ADORA1, ADRA2C, PTGS2 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 2.781E-04 | 8.238E-03 | ADORA1, ADORA2A, MAPT |
BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 2.787E-04 | 8.247E-03 | ADORA1, ADORA2A, APP, CAMK2B, CD38, MAPK1, PTGS2 |
BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 3.092E-04 | 9.038E-03 | MMP12, NFKB1, STAT6, SYK, TLR2 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.092E-04 | 9.038E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 3.348E-04 | 9.719E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 3.356E-04 | 9.719E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.356E-04 | 9.719E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.356E-04 | 9.719E-03 | AURKB, CDK1, PKN1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.023E-20 | 2.783E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.297E-17 | 4.613E-14 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, NR1I2, NR3C1, NR3C2, PARP1, PGR, PPARA, PPARD, PPARG, PTPN1, RORC, TNKS, TP53 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.888E-16 | 6.333E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.506E-14 | 6.557E-12 | ADORA1, ADORA2A, ADRA2A, AURKB, CA2, CA7, CD38, CDK6, CFTR, HCAR2, HIF1A, HTT, KDR, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2, TRPA1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.130E-13 | 6.626E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.316E-13 | 6.974E-11 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1, NR1H4, NR3C1, NR3C2, PGR, RORC, SERPINA6 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.243E-20 | 1.255E-17 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.891E-12 | 1.901E-10 | CYP2C9; CBR1; CYP2C8; PLA2G1B; ALOX5; PLA2G2A; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.045E-11 | 2.028E-09 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.657E-11 | 2.565E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.497E-10 | 1.578E-08 | PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD11B1; FUT7; HSD17B1; ALOX5; HSD17B2; CD38; XDH; CBR1; GAA; PLA2G2A; TYR; CYP2C9; CYP2C8; CYP2A6; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPI |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.551E-11 | 2.028E-09 | HSD11B1; CYP2C9; CBR1; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.732E-11 | 2.028E-09 | CYP2C9; CYP2C8; PLA2G1B; PLA2G2A; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.392E-09 | 3.499E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.144E-09 | 1.149E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.741E-08 | 3.500E-07 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.579E-08 | 9.345E-07 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.015E-08 | 5.510E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.902E-08 | 1.327E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.508E-07 | 2.654E-06 | CDK6; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.057E-08 | 1.091E-06 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 8.861E-08 | 1.272E-06 | SLCO1B1; CA2; SLCO1B3; SLC22A1; NR1H4; CYP3A4; CFTR; ABCG2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.105E-07 | 1.388E-06 | HSD11B1; CYP2C9; CBR1; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.230E-07 | 1.455E-06 | PTPN1; CSNK2A1; SRC; MAPK1; ACP1; MET; PTPRF; IGF1R |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.975E-07 | 2.206E-06 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.643E-07 | 4.537E-06 | GSK3B; SYK; PIK3R1; PTK2; NFKB1; IGF1R; CDK6; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.401E-07 | 4.523E-06 | HCAR2; CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; PPARA; CFTR; NFKB1; TSHR |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.216E-07 | 4.523E-06 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.190E-07 | 3.053E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.817E-07 | 2.831E-06 | FABP4; ADORA1; AKT1; PIK3R1; PTGS2; TSHR; PTGS1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.127E-07 | 4.523E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTGS2; PTK2 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.968E-07 | 5.931E-06 | CAMK2B; CDK6; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.183E-06 | 8.335E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.631E-06 | 1.653E-05 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; PTGS2; MMP9; NFKB1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.456E-06 | 1.592E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PTPRF |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.463E-06 | 9.801E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.506E-06 | 2.912E-05 | POLB; CDK6; PKM; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.968E-07 | 5.931E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.454E-06 | 2.713E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.203E-06 | 8.335E-06 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.048E-06 | 2.891E-05 | ABCC1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.570E-05 | 7.515E-05 | CASP7; PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.271E-05 | 6.387E-05 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.784E-06 | 2.981E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.354E-06 | 2.908E-05 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.357E-05 | 1.436E-04 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.357E-05 | 1.436E-04 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.765E-05 | 8.250E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.179E-06 | 2.891E-05 | ALK; CDK6; AKT1; MAPK1; PIK3R1; TP53 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 8.282E-05 | 3.330E-04 | PLA2G1B; PLA2G2A; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.738E-05 | 1.984E-04 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.358E-05 | 6.657E-05 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.431E-05 | 1.086E-04 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.431E-05 | 1.086E-04 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.296E-04 | 4.583E-04 | ABCC1; CDK6; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 9.096E-05 | 3.585E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.226E-04 | 4.565E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.199E-04 | 4.548E-04 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL; PTPRF |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.015E-04 | 3.922E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.278E-04 | 4.583E-04 | CDK1; AKT1; MAPK1; PGR; PIK3R1; IGF1R |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.509E-04 | 5.142E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.797E-04 | 9.067E-04 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.664E-04 | 1.145E-03 | ADORA2A; ADORA3; ADORA1; NMUR2; ADRA2C; NR3C1; ADRA2A; DRD4; TSHR |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.509E-04 | 5.142E-04 | SLC22A3; SLC22A1; AKT1; MAPK1; PIK3R1; HIF1A |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.701E-04 | 1.145E-03 | ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.837E-04 | 1.169E-03 | BACE1; APP; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.516E-04 | 1.122E-03 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.203E-04 | 1.261E-03 | SYK; SRC; AKT1; MAPK1; PIK3R1; PTGS1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.426E-04 | 1.581E-03 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.390E-04 | 1.298E-03 | CAMK2B; AR; CDK1; MAPK1; PGR; IGF1R |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.382E-04 | 1.833E-03 | SYK; AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.284E-03 | 3.384E-03 | GSK3B; CASP7; AKT1; PIK3R1; PPARA; NFKB1 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.562E-05 | 2.282E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.618E-03 | 3.919E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.086E-03 | 2.951E-03 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.243E-03 | 3.332E-03 | CAMK2B; PKM; AKT1; PYGL; PPARA |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.618E-03 | 3.919E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; PTGS2 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.580E-04 | 2.429E-03 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.750E-04 | 5.863E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.416E-03 | 3.604E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.541E-03 | 3.825E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 9.901E-04 | 2.726E-03 | CA2; PLA2G1B; PLA2G2A; CD38; CFTR |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.300E-04 | 4.583E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.416E-03 | 3.604E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.704E-03 | 5.973E-03 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.889E-03 | 4.415E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 3.058E-03 | 6.609E-03 | AKT1; PPARG; PIK3R1; CFTR; IGF1R |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.436E-03 | 1.082E-02 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 5.436E-03 | 1.082E-02 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.623E-03 | 7.585E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.764E-03 | 1.125E-02 | SYK; CXCR1; AKT1; MAPK1; PIK3R1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.587E-02 | 2.774E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.682E-02 | 2.884E-02 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.000E-02 | 4.824E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.436E-02 | 2.577E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.130E-02 | 3.481E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.693E-02 | 2.884E-02 | GSK3B; CDK6; CDK1; TP53 |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.519E-02 | 2.677E-02 | ADORA2A; PLA2G1B; PLA2G2A; MAPK1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 8.177E-03 | 1.522E-02 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.832E-02 | 3.043E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 8.177E-03 | 1.522E-02 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 6.352E-03 | 1.216E-02 | SYK; AKT1; MAPK1; PIK3R1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 5.885E-03 | 1.137E-02 | CAMK2B; SRC; MMP2; MAPK1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.296E-03 | 3.384E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 4.820E-03 | 9.885E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.673E-03 | 5.970E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.399E-03 | 7.267E-03 | SRC; PIK3R1; MET; PTK2 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.062E-03 | 4.710E-03 | SYK; AKT1; MAPK1; PIK3R1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.949E-03 | 6.443E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.348E-04 | 2.610E-03 | CASP7; CASP1; NFKB1; TLR2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.062E-03 | 4.710E-03 | CXCR1; SRC; MET; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.746E-03 | 4.129E-03 | RORC; STAT6; NFKB1; TLR2 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.084E-02 | 3.434E-02 | CAMK2B; CA2; CFTR |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.800E-02 | 3.016E-02 | AKT1; PPARA; NFKB1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.418E-02 | 2.568E-02 | AKT1; PIK3R1; IGF1R |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.733E-02 | 2.927E-02 | CDK6; CDK1; TP53 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.478E-02 | 2.629E-02 | SRC; MAPK1; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.036E-02 | 1.911E-02 | CASP1; MAPK1; NFKB1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.746E-04 | 9.048E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.450E-03 | 1.223E-02 | PKM; MAPK1; PIK3R1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.726E-03 | 1.125E-02 | CYP2A6; CYP3A4; XDH |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.589E-03 | 7.585E-03 | MAPK1; PIK3R1; NR3C2 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.054E-03 | 1.026E-02 | ABCC1; CFTR; ABCG2 |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 4.138E-03 | 8.575E-03 | FABP2; PLA2G1B; PLA2G2A |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.520E-03 | 3.819E-03 | MAPK1; PPARG; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.679E-03 | 4.018E-03 | AKR1B10; GAA; AKR1B1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.112E-02 | 4.965E-02 | MAOA; TYR |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.634E-02 | 4.270E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.218E-03 | 5.009E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.407E-02 | 2.568E-02 | CA2; CA4 |
hsa00592 | alpha-Linolenic acid metabolism_Homo sapiens_hsa00592 | 1.652E-02 | 2.862E-02 | PLA2G1B; PLA2G2A |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.782E-06 | 2.827E-05 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
NA: NA | HIV infections | NA | AHR |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; ESR1 |
NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; NR3C1; CYP3A4 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | NR3C2; FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; ESR1; HCAR2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ADORA1; TLR2; ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2; ESRRA; MMP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; PGR; NR3C2; CSNK2A1; SYK; FLT3; FLT3; MMP2; ACHE; PTGS2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; NR3C1; PIM1; PARP1; CD38; TLR2; TP53; ESR1; ESR1; CA1; KDR; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; NR3C1; ESR1; ESR1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R; CD38 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
NA: NA | Dyslipidemia | NA | PPARD |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1; ESRRA; NR3C1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; NR3C2; HCAR2; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; SYK; CASP1; MMP3; CAMK2B; PTGS2; PTGS2; PTGS2; PTGS2; ESRRA; NR3C1; TYR; MMP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; HSD11B1; ALOX5; MMP12; PPARD; HCAR2 |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; SRC; ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; FLT3; FLT3; IGF1R; CYP19A1; CDK1; PLA2G2A; ESR1; ESR1; KDR; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; ADORA2A; NR3C1; NR3C1; NR3C1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; ADRA2C |
NA: NA | Obstructive airway diseases | NA | SERPINA6 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; TLR2; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; ADORA2A; ADORA1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; ADRA2C; MMP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
NA: NA | Non-infectious rhinitis | NA | NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; HSD11B1; ESRRA |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3; NR3C1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; SERPINA6; PLA2G1B; ALOX5; MMP13; SYK; MMP12; PTGS1; PTGS2; NR3C1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
C00-D49: Neoplasms | Uterine fibroids | D25 | PGR |
C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; NR3C1; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; HSD11B1; HSD11B1; PTPN1; GSK3B; ADORA1; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA; NR3C1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; PKM; SYK; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADORA2A; NR3C1; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK; ADORA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PPARG; PPARG; APP |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; PARP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; SERPINA6; PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ESRRA; ADORA2A; ADORA1; NR3C1; NR3C1; NR3C1; NR3C1; ADRA2C |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A; HCAR2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1; APP |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; ESR1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
NA: NA | Menopausal disorder | NA | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; PTGS1; ESRRA; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
NA: NA | Geographic retinal atrophy | NA | APP |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C; CA1; CA1 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; ADK |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HCAR2 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NR3C2; HSD11B1; PTPN1; PTPN1; PTGS2; NFKB1; NR3C1; PPARG; PPARG; GPBAR1; PPARD; HCAR2 |
N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PGR; PTGS2; CYP19A1; PPARG |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR |
L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; ADORA1; XDH; ADRA2C |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | PARP1; TLR2; TYR; KDR; KDR |
N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ADK; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ADORA2A; CDK1; ADRA2C; ADRA2A; TRPA1; ESR1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; TLR2; KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |